Highlights of the SARAH Trial
The SARAH trial (Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated hs-cTnI Concentrations During Chemotherapy) provides pivotal evidence for the role of angiotensin receptor-neprilysin inhibitors (ARNI) in the cardio-oncology setting. Key highlights include:
1. Sacubitril-valsartan significantly reduced the incidence of subclinical cardiotoxicity, defined as a >15% reduction in global longitudinal strain (GLS), with a relative risk reduction of approximately 72% compared to placebo.
